Potential new therapeutic options in Behçet's syndrome.

Area of Science:

• Immunology
• Rheumatology
• Ophthalmology

Background:

• Behçet's syndrome is a multisystem disorder with orogenital ulcers, skin lesions, and intraocular inflammation.
• Vascular and central nervous system involvement can lead to significant morbidity and mortality.
• The exact cause is unknown, but autoimmune mechanisms are implicated.

Purpose of the Study:

• To review current therapeutic strategies for Behçet's syndrome.
• To highlight the need for more effective treatments.
• To explore the potential of novel biological agents.

Main Methods:

• Review of existing literature on Behçet's syndrome treatments.
• Analysis of outcomes from open studies using new agents.
• Discussion of emerging biological therapies.

Main Results:

• Conventional therapies include corticosteroids, colchicine, thalidomide, and various immunosuppressants.
• Treatment responses to conventional agents are variable.
• Open studies suggest promising results with recombinant interferon-alpha.

Conclusions:

• There is a need for more effective and rational treatments for Behçet's syndrome.
• New biological agents offer promise for improved management.
• Further research into novel therapies may also elucidate disease aetiopathogenesis.